{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:06:23Z","timestamp":1785495983197,"version":"3.56.0"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2023-0223_abs_001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Phosphodiesterase 5 inhibitors (PDE5-is) are\u00a0used worldwide as first line therapy for erectile dysfunction (ED). Current literature reported data on the\u00a0warning association between PDE5-is use and the development of cutaneous melanoma. However, these data\u00a0are contrasting, thus we aim to summarise evidence regarding this association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2023-0223_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>A systematic review of all published articles related to the effects of PDE5-is in the development of cutaneous melanoma was performed. PubMed, EMBASE, and Cochrane library were queried for all the published studies indexed up to the 26th of May 2023. A combination of keywords related to PDE5-is and melanoma were used. Only original studies based on human subjects in the English language were included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2023-0223_abs_003\">\n                    <jats:title>Summary and Outlook<\/jats:title>\n                    <jats:p>Of 505 articles identified, only eight original articles were considered for further analysis. Overall, five of\u00a0the selected articles including 657,984 subjects agrees on an increased risk of developing melanoma in PDE5-is users. On the other hand, three original articles based on data regarding 360,915 subjects, disagree with the previous statement declaring any association between PDE5-i use and melanoma. Current literature still reports contrasting data regarding the association between PDE5-is assumption and increased risk of melanoma, but a possible association is described, bringing attention to higher risk melanoma category of patients. More clinical studies are needed to clarify the impact of PDE5-is in the development and progression of melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2023-0223","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T09:20:45Z","timestamp":1700472045000},"page":"691-697","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review"],"prefix":"10.1515","volume":"34","author":[{"given":"Simone","family":"Cilio","sequence":"first","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology , Urology Unit, University of Naples \u201cFederico II\u201d , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Briatico","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Brancaccio","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Capone","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology , Urology Unit, University of Naples \u201cFederico II\u201d , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[{"name":"Division of Urology, European Institute of Oncology , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Imbimbo","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology , Urology Unit, University of Naples \u201cFederico II\u201d , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology\/Unit of Urology, URI, IRCCS Ospedale San Raffaele , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, University of Campania , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Reproductive Sciences and Odontostomatology , Urology Unit, University of Naples \u201cFederico II\u201d , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_001","doi-asserted-by":"crossref","unstructured":"Salonia, A, Bettocchi, C, Boeri, L, Capogrosso, P, Carvalho, J, Cilesiz, NC, et al.. European association of urology guidelines on sexual and reproductive health\u20142021 update: male sexual dysfunction. Eur Urol 2021;80:333\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2021.06.007.","DOI":"10.1016\/j.eururo.2021.06.007"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_002","doi-asserted-by":"crossref","unstructured":"Giuliano, F, Montorsi, F, Mirone, V, Rossi, D, Sweeney, M. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000;164:708\u201311. https:\/\/doi.org\/10.1097\/00005392-200009010-00021.","DOI":"10.1097\/00005392-200009010-00021"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_003","doi-asserted-by":"crossref","unstructured":"Capece, M, Montorio, D, Comune, C, Aveta, A, Melchionna, A, Celentano, G, et al.. Retinal and optic disc vascular changes in patients using long-term tadalafil: a prospective non-randomized matched-pair study. Diagn Basel Switz 2021;11:802. https:\/\/doi.org\/10.3390\/diagnostics11050802.","DOI":"10.3390\/diagnostics11050802"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_004","doi-asserted-by":"crossref","unstructured":"Giuliano, F, Jackson, G, Montorsi, F, Martin-Morales, A, Raillard, P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64:240\u201355. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02254.x.","DOI":"10.1111\/j.1742-1241.2009.02254.x"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_021","doi-asserted-by":"crossref","unstructured":"Pezone, G, Coll\u00e0 Ruvolo, C, Cilio, S, Fraia, A, Di Mauro, E, Califano, G. The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source. Int J Impot Res 2023.","DOI":"10.1038\/s41443-023-00762-w"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_005","doi-asserted-by":"crossref","unstructured":"Loeb, S, Ventimiglia, E, Salonia, A, Folkvaljon, Y, Stattin, P. Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst 2017;109:1\u20133. https:\/\/doi.org\/10.1093\/jnci\/djx086.","DOI":"10.1093\/jnci\/djx086"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_006","doi-asserted-by":"crossref","unstructured":"Garbe, C, Keim, U, Eigentler, TK, Amaral, T, Katalinic, A, Holleczek, B, et al.. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol JEADV 2019;33:1272\u201380. https:\/\/doi.org\/10.1111\/jdv.15322.","DOI":"10.1111\/jdv.15322"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_007","doi-asserted-by":"crossref","unstructured":"Wu, N, Sun, H, Sun, Q, Zhang, F, Ma, L, Hu, Y, et al.. Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis. BMC Cancer 2023;23:414. https:\/\/doi.org\/10.1186\/s12885-023-10891-6.","DOI":"10.1186\/s12885-023-10891-6"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_008","doi-asserted-by":"crossref","unstructured":"Briatico, G, Mancuso, P, Argenziano, G, Longo, C, Mangone, L, Moscarella, E, et al.. Trends in cutaneous melanoma mortality in Italy from 1982 to 2016. Int J Dermatol 2022;61:1237\u201344. https:\/\/doi.org\/10.1111\/ijd.16173.","DOI":"10.1111\/ijd.16173"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_009","doi-asserted-by":"crossref","unstructured":"Huang, F, Santinon, F, Flores Gonz\u00e1lez, RE, Del Rinc\u00f3n, SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol 2021;11:756001. https:\/\/doi.org\/10.3389\/fonc.2021.756001.","DOI":"10.3389\/fonc.2021.756001"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_010","doi-asserted-by":"crossref","unstructured":"Dhayade, S, Kaesler, S, Sinnberg, T, Dobrowinski, H, Peters, S, Naumann, U, et al.. Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth. Cell Rep 2016;14:2599\u2013610. https:\/\/doi.org\/10.1016\/j.celrep.2016.02.028.","DOI":"10.1016\/j.celrep.2016.02.028"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_011","doi-asserted-by":"crossref","unstructured":"Stone, L. Sexual dysfunction: PDE5i and melanoma-correlation is not causation. Nat Rev Urol 2015;12:418. https:\/\/doi.org\/10.1038\/nrurol.2015.170.","DOI":"10.1038\/nrurol.2015.170"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_012","doi-asserted-by":"crossref","unstructured":"Crocetto, F, Cuomo, V, Santoro, C, Fiorillo, L, Barone, B, Arcaniolo, D, et al.. New possibilities in heart failure: the effects of tadalafil on diastolic function in patients undergoing robot-assisted radical prostatectomy. Appl Sci 2022;12:5629. https:\/\/doi.org\/10.3390\/app12115629.","DOI":"10.3390\/app12115629"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_013","doi-asserted-by":"crossref","unstructured":"Li, WQ, Qureshi, AA, Robinson, KC, Han, J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014;174:964\u201370. https:\/\/doi.org\/10.1001\/jamainternmed.2014.594.","DOI":"10.1001\/jamainternmed.2014.594"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_014","doi-asserted-by":"crossref","unstructured":"Loeb, S, Folkvaljon, Y, Lambe, M, Robinson, D, Garmo, H, Ingvar, C, et al.. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015;313:2449\u201355. https:\/\/doi.org\/10.1001\/jama.2015.6604.","DOI":"10.1001\/jama.2015.6604"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_015","doi-asserted-by":"crossref","unstructured":"Lian, Y, Yin, H, Pollak, MN, Carrier, S, Platt, RW, Suissa, S, et al.. Phosphodiesterase type 5 inhibitors and the risk of melanoma skin cancer. Eur Urol 2016;70:808\u201315. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.035.","DOI":"10.1016\/j.eururo.2016.04.035"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_016","doi-asserted-by":"crossref","unstructured":"Matthews, A, Langan, SM, Douglas, IJ, Smeeth, L, Bhaskaran, K. Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 2016;13:e1002037. https:\/\/doi.org\/10.1371\/journal.pmed.1002037.","DOI":"10.1371\/journal.pmed.1002037"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_017","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd, A, Schmidt, SAJ, Olesen, AB, Achacoso, N, Van Den Eeden, SK, Hallas, J, et al.. Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer 2016;115:895\u2013900. https:\/\/doi.org\/10.1038\/bjc.2016.248.","DOI":"10.1038\/bjc.2016.248"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_018","doi-asserted-by":"crossref","unstructured":"Shkolyar, E, Li, S, Tang, J, Eisenberg, ML. Risk of melanoma with phosphodiesterase type 5 inhibitor use among patients with erectile dysfunction, pulmonary hypertension, and lower urinary tract symptoms. J Sex Med 2018;15:982\u20139. https:\/\/doi.org\/10.1016\/j.jsxm.2018.05.002.","DOI":"10.1016\/j.jsxm.2018.05.002"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_019","doi-asserted-by":"crossref","unstructured":"Wayne, G, Demus, T, Jivanji, D, Atri, E, Herzog, B, Wong, V, et al.. Use of phosphodiesterase-5 inhibitors and the incidence of melanoma. Cancer Epidemiol 2022;81:102251. https:\/\/doi.org\/10.1016\/j.canep.2022.102251.","DOI":"10.1016\/j.canep.2022.102251"},{"key":"2025121209005532254_j_jbcpp-2023-0223_ref_020","doi-asserted-by":"crossref","unstructured":"Lui, JL, Shaw, NM, Abbasi, B, Hakam, N, Breyer, BN. Adverse reactions of PDE5 inhibitors: an analysis of the World Health Organization pharmacovigilance database. Andrology 2023;11:1408\u201317. https:\/\/doi.org\/10.1111\/andr.13430.","DOI":"10.1111\/andr.13430"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0223\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:23:44Z","timestamp":1765538624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2023-0223\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,21]]},"published-print":{"date-parts":[[2023,11,30]]}},"alternative-id":["10.1515\/jbcpp-2023-0223"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2023-0223","relation":{},"ISSN":["0792-6855","2191-0286"],"issn-type":[{"value":"0792-6855","type":"print"},{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}